UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000031922
Receipt number R000036328
Scientific Title A study on the application method for prevention/reduction of the local irritation with the benzoyl peroxide preparations for acne vulgaris patients.
Date of disclosure of the study information 2018/03/27
Last modified on 2019/03/29 14:30:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on the application method for prevention/reduction of the local irritation with the benzoyl peroxide preparations for acne vulgaris patients.

Acronym

A study for the prevention of local irritation of the BPO preparation

Scientific Title

A study on the application method for prevention/reduction of the local irritation with the benzoyl peroxide preparations for acne vulgaris patients.

Scientific Title:Acronym

A study for the prevention of local irritation of the BPO preparation

Region

Japan


Condition

Condition

acne vulgaris

Classification by specialty

Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Study for Japanese acne vulgaris patients, regarding the application method to demonstrate a clinical response to expect with prevention/reduction of the local irritation with the BPO preparation.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase IV


Assessment

Primary outcomes

A local irritating evaluation (accompanying symptom) during testing period of 12 weeks: Erythema, desquamation, skin drying, itching, irritation / incandescence

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment



Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Medicine Behavior,custom

Interventions/Control_1

Gradual increase application group (Epiduo Gel) 20 subjects;BPO preparation use experience.
Application once a day consecutive for appropriate amount, 12 weeks

Interventions/Control_2

Non-gradual increase application group (Epiduo Gel) 20 subjects;BPO preparation use experience.
Application once a day consecutive for appropriate amount, 12 weeks

Interventions/Control_3

Gradual increase application group (BPO Gel) 40 subjects;BPO preparation use experience 20 subjects,no BPO preparation use experience 20 subjects.
Application once a day consecutive for appropriate amount, 12 weeks

Interventions/Control_4

Non-gradual increase application group (BPO Gel) 40 subjects;BPO preparation use experience 20 subjects,no BPO preparation use experience 20 subjects.
Application once a day consecutive for appropriate amount, 12 weeks

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Moderate acne vulgaris (6-20 inflammatory rashes on one side of the face)
2) Written consent provided after receiving an explanation of the study content
3) Age >=20 years at the time of obtaining consent.

Key exclusion criteria

1) Treated for acne vulgaris within one month before the study
2) Contraindicated for the investigational drugs
3) Continuous use of nonsteroidal anti-inflammatory drugs (such as ibuprofen)
4) Pregnant or possibly pregnant women, lactating women, and women who wanted to become pregnant during the study period.
5) Judged as ineligible by the physician directing the study
6) Participation in another clinical study or post-marketing surveillance of other drugs for acne vulgaris within six months before the study.

Target sample size

120


Research contact person

Name of lead principal investigator

1st name Makoto
Middle name
Last name Kawashima

Organization

Non-Profit Organization Health Institute Research of Skin

Division name

vice chief director

Zip code

101-0047

Address

1-8-9 Kamikanda, Chiyoda-ku, Tokyo, Japan

TEL

03-3256-2575

Email

kawashima.makoto@twmu.ac.jp


Public contact

Name of contact person

1st name Yoshitaka
Middle name
Last name Ogaki

Organization

EBC&M LLC.

Division name

Clinical Business Department

Zip code

105-0011

Address

ShibaMatsuo BUILDING 4F 2-9-1, Shibakoen, Minato-ku, Tokyo, Japan

TEL

03-6435-3833

Homepage URL


Email

yoshitaka_ogaki@ebc-m.com


Sponsor or person

Institute

NPO Health Institute Research of Skin

Institute

Department

Personal name



Funding Source

Organization

Maruho Co.,Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB of Shinkokai

Address

Hakuaido Building 3F, 1-18-7, Nishishinjyuku, Shinjyuku-ku, Tokyo, Japan

Tel

03-5354-7388

Email

kawabata@hifuka.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 03 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

121

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 03 Month 16 Day

Date of IRB

2018 Year 03 Month 27 Day

Anticipated trial start date

2018 Year 04 Month 01 Day

Last follow-up date

2018 Year 11 Month 30 Day

Date of closure to data entry

2018 Year 12 Month 20 Day

Date trial data considered complete

2019 Year 03 Month 08 Day

Date analysis concluded

2019 Year 03 Month 28 Day


Other

Other related information



Management information

Registered date

2018 Year 03 Month 27 Day

Last modified on

2019 Year 03 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036328


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name